Montelucaste Krka (Montelukast)

Montelukast, the active ingredient in Montelucaste Krka, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma and allergic rhinitis by blocking cysteinyl leukotriene receptors that contribute to airway inflammation and nasal symptoms.

GNH USA supplies Montelucaste Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Montelukast acts on the leukotriene pathway to control respiratory and allergic conditions.

- Asthma: helps control chronic symptoms and reduces exacerbations in patients with persistent asthma. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after vigorous physical activity.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Abdominal pain: discomfort in the stomach area, usually self‑limiting. - Cough: non‑productive cough without infection. - Dyspepsia: indigestion or feeling of fullness. - Fatigue: generalized tiredness. - Nausea: sensation of needing to vomit.

Serious or Rare Side Effects: - Allergic reactions: including angioedema, urticaria or anaphylaxis. - Neuropsychiatric events: mood changes, depression, suicidal thoughts or behavior. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Hepatic injury: elevated liver enzymes or hepatitis.

When prescribing Montelukast, clinicians should consider several safety precautions.

- Assess asthma control before initiating: ensure the patient has persistent asthma that requires a controller medication. - Monitor for neuropsychiatric symptoms: watch for mood changes, depression, anxiety or suicidal thoughts. - Use caution in hepatic impairment: adjust therapy if liver function tests are abnormal. - Avoid in patients with known hypersensitivity to montelukast or any tablet excipients. - Pregnancy and lactation: discuss potential risks with the prescriber before use. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Montelukast can interact with other medicines that affect its metabolism or share similar pharmacologic effects.

Major Interactions (Avoid): - Ritonavir (strong CYP3A4 inhibitor): may increase montelukast plasma concentrations. - Ketoconazole (CYP3A4 inhibitor): may raise exposure and risk of side effects. - Phenobarbital (CYP inducer): may reduce montelukast effectiveness.

Moderate Interactions (Monitor Closely): - Fluticasone inhaler: additive effect on asthma control may require dose adjustment. - Zafirlukast (another leukotriene antagonist): concurrent use can increase risk of adverse reactions. - Warfarin: monitor INR as montelukast may alter anticoagulant metabolism.